Annual report on adverse events related with vaccines use in Calabria (Italy): 2012

Orietta Staltari, Felisa Cilurzo, Benedetto Caroleo, Alexia Greco, Francesco Corasaniti, Maria Antonietta Genovesi, Luca Gallelli

Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, 1Azienda Sanitaria Provinciale di Catanzaro, Italy

ABSTRACT

Vaccines are administered to large population of healthy individuals, particularly to millions of infants every year, through national immunization programs. Although vaccines represent a good defense against some infectious diseases, their administration may be related with the development of adverse vaccine events (AVEs); therefore their use is continually monitored to detect these side effects. In the presents work, we reported the suspected AVEs recorded in 2012 in Calabria, Italy. We performed a retrospective study on report forms of patients that developed AVEs in Calabria from January 1, 2012 to December 31, 2012. Naranjo score was used to evaluate the association between AVEs and vaccines and only suspected AVEs definable as certain, probable, or possible were included in this analysis. During the study period, we evaluated 461 records of adverse drug reactions (ADRs) and 18 (3.9%) were probably induced by vaccination. AVEs were common in females (almost 77.7%) and in children aged 0-3 years. The largest number of non-serious AVEs involved “skin and subcutaneous tissue disorders” and “general disorders and administration site conditions.” In conclusion, we documented that in Calabria the total number of AVEs is very low and it may be useful to increase the pharmacovigilance culture in order to evaluate the safety of these products in large populations.

Key words: Adverse events, Calabria, children, immunization, vaccines

INTRODUCTION

Vaccines are administered to large population of healthy individuals, particularly to millions of infants every year, through national immunization programs.1,2

The recommended childhood vaccination schedule has changed dramatically over the years, with children now receiving up to 20 vaccines, including multiple combination vaccines administrations, before the age of 6 years. The current Italian National Immunization Program is carried out through vaccination clinics within the Italian National Health Service. As some vaccinations are mandatory by law for all newborns (diphtheria, tetanus, poliomyelitis, hepatitis B) the network of vaccination clinics is capillary distributed all over the Italian territory.3

In Italy, the current vaccination schedule includes three doses of diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type...
Staltari, et al.: Vaccines and adverse events

Up to date, no data are available on vaccines’ safety, therefore, the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA) established a surveillance system to intensively monitor AVEs based on spontaneous reports.

Adverse events are defined as health effects that occur after immunization that may or may not be related to the vaccine.

In Italy, the signals of AVEs can be obtained with spontaneous reporting of medical records. Available data include the following information: Type of vaccine received, date of vaccination, manufacturer, lot number, and injection site, onset of AVE, current illnesses or medication, history of adverse events following vaccination, concurrent vaccinations (those given during the same visit) and demographic information about the recipient (age, gender, race). In the present work, we reported the suspected AVEs recorded in 2012 in Calabria, Italy.

**MATERIALS AND METHODS**

In agreement with our previous papers, we performed a retrospective study on report forms of patients who developed AVEs in Calabria from January 1, 2012 to December 31, 2012.

Naranjo score was used to evaluate the association between AVEs and vaccines and only suspected AVEs definable as certain, probable, or possible were included in this analysis.

We analyzed data with respect to source of reporting, gender, age, vaccine suspected of causing the event, seriousness, and system organ class (SOC).

**Table 1: Vaccination schedule for infants and childhood in Italy**

| Age of child | Vaccines |
|--------------|----------|
|              | DTaP     | Hib     | Hepa B | IPV | MMR | PVC | Men C | Varicella | Influenza | HPV |
| Birth        | Yes      | Yes     | Yes    | Yes | Yes |     |       |           |           | Yes |
| 3 months     | Yes      | Yes     | Yes    | Yes | Yes |     |       |           |           | Yes |
| 5 months     | Yes      | Yes     | Yes    | Yes | Yes |     |       |           |           | Yes |
| 6 months     | Yes      | Yes     | Yes    | Yes | Yes |     |       |           |           | Yes |
| 11 months    | Yes      | Yes     | Yes    | Yes | Yes | Yes |       |           |           | Yes |
| 13 months    | Yes      | Yes     | Yes    | Yes | Yes | Yes | Yes   |           |           | Yes |
| 15 months    | Yes      | Yes     | Yes    | Yes | Yes | Yes | Yes   |           |           | Yes |
| 24 months    | Yes      | Yes     | Yes    | Yes | Yes | Yes | Yes   |           |           | Yes |
| 36 months    | Yes      | Yes     | Yes    | Yes | Yes | Yes | Yes   |           |           | Yes |
| 5-6 years    | Yes (dTaP) |         |         |     |     |     |       |           |           | Yes |
| 11-12 years  | Yes      | Yes     | Yes    | Yes | Yes | Yes |       |           |           | Yes |
| 14-15 years  | Yes      | Yes     | Yes    | Yes | Yes | Yes |       |           |           | Yes |

DTaP=Diffo-tetanus-acellular pertussis vaccine; dTaP=Diffo-tetanus-acellular pertussis vaccine for adults; IPV=Inactivated antipolio vaccine; Hepa B=Hepatitis B vaccine (at birth only for newborns of HBsAg+mother; all others start immunization at 3 months of age); Hib=Haemophilus Influenzae type B vaccine; MMR=Measles, mumps, rubella vaccine; PVC=Pneumococcal heptavalent conjugate vaccine; MEN C=Meningococcal C conjugate vaccine; HPV=Human papilloma vaccine
RESULTS

During the study time-window, we found 461 records of adverse drug reactions (ADRs) and 18 (3.9%) were probably related to vaccination.

Our data shows that the sources of reporting were mainly doctors working in hospital (31.7%) [Figure 1], and AVEs were more common in females (almost 77.7%) and in the children aged 0-3 years [Table 2].

Five reports (27.7%) involved serious events that occurred with Priorix tetra®, a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain), Wistar RA 27/3 rubella and Oka varicella strains of viruses [Table 3].

The largest numbers of non-serious AVEs involved “skin and subcutaneous tissue disorders” and “general disorders and administration site conditions” [Table 4].

DISCUSSION

In the present paper, we documented that 18 of 461 records of ADRs were probably related to vaccine administration in Calabria, Italy.

These data are lower in respect to the mean Italian data and probably it is related with the underreporting of ADRs in Calabria.

However, a previous Italian study documented an increased risk of developing immune thrombocytopenic purpura during MMR vaccine (odds ratio 2.4).[16] In our study, we did not record this skin manifestation, but we reported the development of serious AVEs (i.e., seizures) in 27.7% of records during the immunization with measles — mumps — rubella — varicella vaccine (MMRV) and with diphtheria and tetanus toxoids (DTP).

These data are in agreement with other papers that documented the development of seizures, after the immunization with DTP[17-20] and MMRV.[21]

In our study, we documented the development of apnea, cyanosis and muscular flaccidity in a 2-year-old girl after

![Figure 1: Medical doctors source of reporting](image)

**Table 2: Total number of adverse drug reactions reported for vaccines by age group**

| Age group (years) | <2 | 2-3 | 4-6 | 7-11 | 12-17 | 18-64 | >65 | Total ADRs |
|-------------------|----|-----|-----|------|-------|-------|-----|-----------|
| Vaccines          |    |     |     |      |       |       |     |           |
| Infanrix® (Diphtheria, tetanus, pertussis acellular, and poliomyelitis inactivated) | 3  |     |     |      |       |       |     | 3         |
| Prevenar® (pneumococcal polysaccharide) | 1  | 1   | 1   |      |       |       |     | 3         |
| Prevenar 13® (pneumococcal polysaccharide serotype 13) |     |     |     | 1    |       |       |     | 1         |
| Priorix Tetra® (measles, mumps, rubella, varicella) | 2  |     |     |      | 2     |       |     | 4         |
| Meningitec® (meningococcal C conjugate) | 1  | 1   |     |      | 2     |       |     | 4         |
| Rudivax® (Attenuated rubella vaccine) | 1  |     |     |      |       |       |     | 1         |
| Cervarix® (nolive virus against HPV) |     |     |     | 1    |       |       |     | 1         |
| Intanza® (Influenza virus inactivated, split) | 2  |     |     |      |       |       |     | 2         |
| Fluad® (Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C.1) | 2  |     |     |      |       |       |     | 2         |
| Revaxis® (Diphtheria, tetanus and poliomyelitis inactivated) | 1  |     |     |      |       |       |     | 1         |

HPV=Human papilloma virus

**Table 3: Reporting for suspected serious adverse events reported by age group**

| Age group (years) | <2 | 2-3 | 4-6 | 7-11 | 12-17 | 18-64 | >65 |
|-------------------|----|-----|-----|------|-------|-------|-----|
| ADRs serious      |    |     |     |      |       |       |     |
| Febrile convolution | Prevenar® | Priorix Tetra® |
| Seizure partial   | Infanrix® | Priorix Tetra® |
| Fever High, cyanosis, tremor | Priorix Tetra® |
| Polyneuritis/arthritis | Revaxis® |
MENINGITEC® administration (see Table 2). Paradoxically, this event was reported as nonserious, although the child was admitted to intensive care unit.

In a previous study, Zhou et al.[22] evaluated, over 10 years, 128,717 reports with >1.9 billion doses of human vaccines administered in patients of all the age (from <1 year up to 64 years), and documented an higher number of AVEs in the age groups of 1-6 years (26.7%) and 18-64 years (32.65%). In this study, the most commons AVEs were fever, injection-site hypersensitivity and edema, and local vasodilatation.[22]

In agreement with this study, we documented that in adults the most common reactions were pain, redness, and swelling in the site of administration. These manifestations were nonserious with a favorable evolution.

Moreover, we reported the development of hyper-glycemia after administration of Fluad® in two elderly diabetic patients (aged 73 and 76 years, respectively).

However, up to date, no conclusive data are available concerning the association between vaccines and diabetes. In fact, although Classen et al.[23] documented an association between Haemophilus influenzae type b (Hib) vaccines and diabetes in children, two separate expert panels reviewing published data did not report a causal relationship between vaccines and diabetes.[24,25]

Unfortunately, we are not able to explain the possible association between vaccine and diabetes because several data were missing in the report form and this represents a limitation of this study.

In fact, spontaneous report of AVEs is a passive surveillance system, and the large number of reports increases the likelihood that some reports may not be adequately checked for accuracy.

In agreement with this point we documented that the higher number of AVEs were reported by hospital doctors, probably because hospital doctors are more prone to report AVEs, although it is also probable that they have more time to spend for the study of AVEs than for other studies.

Spontaneous reporting systems suffer from different barriers such as incomplete recognition of suspected ADRs; barriers to reporting and insufficient data quality, which may result in underreporting of important serious and rare ADRs. ADRs that are nonserious or known to be related to the vaccines may be over reported.[22]

The report forms often have a missing or incorrect data including comorbidity, vaccines coadministered, accurate descriptions of the event that occurred, and outcome of ADRs. Some reports are likely to be unrelated to vaccinations. Nevertheless, spontaneous reports are still the source of information about new and previously unrecognized ADRs and an important postmarketing safety surveillance.[26]

The study of AVEs is a continuous process, starting from the initial reports and represents the door to studies of drug-epidemiology and quantitative risk assessment.[27,28] This is relevant for vaccines because it is not possible to know adverse effects during immunization due to limitations of clinical trials.[29,30]

Since vaccines are given to millions of infants annually, it is imperative that health authorities have scientific data from synergistic toxicity studies on all combinations of vaccines that infants might receive. Finding instruments to increase vaccine safety should be the highest priority.[1]

As vaccines are used in healthy people, their safety must be excellent to be accepted. Their monitoring after marketing is the sole way to detect rare ADRs. This surveillance is made through reporting of AVEs to the PVRC.[6]

In conclusion, we documented that in Calabria, the total number of AVEs is very low and it may be useful to increase the pharmacovigilance culture in order to evaluate the safety of these products in large population.

---

Table 4: Reporting for suspected non-serious adverse events reported by age group

| Age group (years) | <2 | 2-3 | 4-6 | 7-11 | 12-17 | 18-64 | >65 |
|------------------|----|-----|-----|------|-------|-------|-----|
| Urticaria/Urticaria-like rash |    |     |     |      |       |       |     |
| Injection Site (redness, swelling, pain) |    |     |     |      |       |       |     |
| Apnea, cyanosis, muscular flaccidity |    |     |     |      |       |       |     |
| Lipotimia and vomiting | Meningitec® |    |     |       |       |       |     |
| Erythema | Prevenar® |    |     |       |       |       |     |
| Fever | Prevenar® |    |     |       |       |       |     |
| Rubella rash | Meningitec® |    |     |       |       |       |     |
| Hyperglycemia | Rudivax® |    |     |       |       |       |     |

---
ACKNOWLEDGMENTS

The Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA) is kindly acknowledged for its financial and technical support.

REFERENCES

1. Goldman GS, Miller NZ. Relative trends in hospitalizations and mortality among infants by the number of vaccines doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010. Hum Exp Toxicol 2012;31:1012-21.

2. Aagaard L, Hansen EW, Hansen EH. Adverse events following immunization in children: Retrospective analysis of spontaneous reports over a decade. Eur J Clin Pharmacol. 2011 Mar;67(3):283-8.

3. Italian Ministry of Health. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1721_allegato.pdf [Last accessed on 2013 Jul 31].

4. Chen RT, Hibbs B. Vaccine safety: Current and future challenges. Pediatr Ann 1998;27:445-55.

5. Chen RT, Rastogi SC, Mullen JR, Hayes SW, DiMaggio JM, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994;12:542-50.

6. Autret-Leca E, Bensouda-Grimaldi L, Jonville-Béra AP, Beau-Salinas F. Pharmacovigilance of vaccines. Arch Pediatr. 2002;9:395-400.

7. Dettman G, Kalokerinos A, Dettmann I. Vitamin C, Nature’s miraculous healing missile! Frederick Todd. Melbourne 1993. p. 1-422.

8. Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol 2006;21:170-2.

9. Ellenberg SS, Shen RT. The complicated task of monitoring vaccine safety. Public Health Rep 1997;112:10-20.

10. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases, vaccine safety. Chap 15. Washington DC: Government Printing Office; 1997.

11. Farsak U, Tzanakakis G, Diamanti-Kandarakis E. Incidence of adverse drug events and medication errors in intensive care units: A prospective multicenter study. Pharmacoepidemiol Drug Saf 2010;19:872-5.

12. Classen JB. The timing of immunization affects the development of diabetes in rodents. Autoimmunity 1996;24:137-45.

13. Childhood immunizations and type 1 diabetes: Summary of an Institute for Vaccine Safety Workshop. The Institute for Vaccine Safety Diabetes Workshop Panel. Pediatr Infect Dis J 1999;18:217-22.

14. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41.

15. Parretta E, Iannelli B, Ferrari F, Rossi F, Capuano A. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine 2011;29:3708-13.

16. Scicchitano F, Giofrè C, Palleria C, Mazzitello C, Ciriaco M, Gallelli L, et al. Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis. J Res Med Sci 2012;17:872-5.

17. Howard CR, Howe CJ, Fineberg HV, editors. Adverse effects of Pertussis and Rubella Vaccines: A report of the committee to review the adverse consequences of Pertussis and Rubella Vaccines. Washington, DC: National Academy Press; 1994.

18. Miller DL, Wadsworth J, Ross E. Severe neurological illness: Further analyses of the British National Childhood Encephalopathy Study. Tokai J Exp Clin Med 1998;13(suppl):145-53.

19. Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/ pertussis and measles/mumps/rubella vaccines. Lancet 1995;345:567-9.

20. Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mulloloy JP, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001;345:656-61.

21. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Update: Recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep 2008;57:258-60.

22. Zhou W, Pool V, Isakander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) — United States, 1991-2001. MMWR Surveill Summ 2002;51:1-24.

23. Sjøtt J, Reppe LA, Roland PD, Westergren T. A question-answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): A descriptive study. BMJ Open 2012;2:e000642.

24. Benkrisane RR, Aboualq R, Haineur CC, Ech-Cherif F, Kettani SS, Azzouz AA, et al. Incidence of adverse drug events and medication errors in intensive care units: A prospective multicenter study. J Patient Saf 2009;5:16-22.

25. Napoleone E. Children and ADRs (Adverse Drug Reactions). Ital J Pediatr 2010;36:4.